[go: up one dir, main page]

WO2013046194A2 - Nouveaux marqueurs de référence pour le fumarate de fésotérodine - Google Patents

Nouveaux marqueurs de référence pour le fumarate de fésotérodine Download PDF

Info

Publication number
WO2013046194A2
WO2013046194A2 PCT/IB2013/050141 IB2013050141W WO2013046194A2 WO 2013046194 A2 WO2013046194 A2 WO 2013046194A2 IB 2013050141 W IB2013050141 W IB 2013050141W WO 2013046194 A2 WO2013046194 A2 WO 2013046194A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
fesoterodine
bag
sealed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/050141
Other languages
English (en)
Other versions
WO2013046194A3 (fr
Inventor
Venkat Raman JAYARAMAN
Sundara Kalyana BALAJI
Samir Patel
Indrajit Thakor
Viral Maheshbhai Parekh
Mahesh LADANI
Chetan PATIL
Ronak Patel
Darshan PARMAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alembic Pharmaceuticals Ltd
Original Assignee
Alembic Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Pharmaceuticals Ltd filed Critical Alembic Pharmaceuticals Ltd
Priority to US14/370,577 priority Critical patent/US9440910B2/en
Priority to EP13704230.5A priority patent/EP2780317A2/fr
Publication of WO2013046194A2 publication Critical patent/WO2013046194A2/fr
Publication of WO2013046194A3 publication Critical patent/WO2013046194A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
    • B65D81/20—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas
    • B65D81/2007—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas under vacuum
    • B65D81/2023—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas under vacuum in a flexible container
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/264—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing liquids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/06—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton from hydroxy amines by reactions involving the etherification or esterification of hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility

Definitions

  • the present invention relates to novel compounds useful as reference markers for the analysis of Fesoterodine and pharmaceutical formulations thereof.
  • the present invention deals with the new impurities of Fesoterodine, Fesoterodine symmetric dimer impurity (Formula II) and asymmetric dimer impurity (Formula III), which occur due to chemical instability of the target substance.
  • Process for preparing and isolating thereof includes methods of analytic control of the production process and quality of the target substance.
  • Fesoterodine is [2-[(li?)-3-(Di (propan-2-yl) amino)- l-phenylpropyl]-4-(hydroxymethyl) phenyl] 2-methylpropanoate and represented by formula (I).
  • Fesoterodine is cholinergic antagonist and muscarinic antagonist. Fesoterodine is rapidly de-esterified to its active metabolite, (R)-2-(3- diisopropylamino- 1 -phenylpropyl)-4-hydroxymethyl -phenol, or 5-hydroxy methyl tolterodine, which is a muscarinic receptor antagonist. Fesoterodine is used as Urinary Incontinence Products. It is used to treat overactive bladder.
  • Tolterodine and other 3,3-diphenylpropylamine analogs were first described in US patent 5,382,600. Said patent described several methods for preparing tolterodine and its analogs generally based a process for the preparation of Tolterodine.
  • Fesoterodine obtained by the processes described in the above prior art does not have satisfactory purity for pharmaceutical use.
  • a drugs manufacturer In order to secure marketing approval for a new drug product, a drugs manufacturer must submit detailed evidence to the appropriate regulatory authority to show that the product is suitable for release on to the market.
  • the regulatory authority must be satisfied, inter alia, that the active agent is acceptable for administration to humans and that the particular formulation which is to be marketed is free from impurities at the time of release and has an appropriate shelf-life.
  • impurities in pharmaceutically active agents and formulations containing them include residual amounts of synthetic precursors to the active agent, by-products which arise during synthesis of the active agent, residual solvent, isomers of the active agent, contaminants which were present in materials used in the synthesis of the active agent or in the preparation of the pharmaceutical formulation, and unidentified adventitious substances.
  • Other impurities which may appear on storage include substances resulting from degradation of the active agent, for instance by oxidation or hydrolysis.
  • API Active Pharmaceutical Ingredient
  • FDA American Food and Drug Administration
  • ICH European Conference on Harmonization
  • the purpose is to achieve maximum safety of use of the medicament in the clinical practice.
  • National administration and control authorities usually require the content of an individual impurity in the API not to exceed the limit of 0.1%. All substances (generally referred to as impurities) contained in the API in a quantity exceeding 0.1% should be isolated and characterized in accordance with ICH recommendations. Nevertheless, the content of substances with a known structure (isolated and characterized) in a pharmaceutically acceptable ingredient should not exceed the limit of 0.15%.
  • Impurities present in the API are then determined by the relative position of the peak in the HPLC or GC chromatogram while the peak position is usually expressed as the time (in minutes) necessary for the impurity to travel from the point of sample injection to the HPLC or GC column filled with a suitable sorbent to the detection place.
  • the time necessary for a chemical substance (e.g. API or impurity) to get from the injection point to the detector under standard conditions is referred to as the "retention time”.
  • Retention times (RT) related to the retention time of a standard (usually RT of the API) are called “relative retention times”.
  • the relative retention time (RRT) of the API usually takes the value 1 , components that need a shorter time to travel to the detector manifest lower relative retention times than 1 while components travelling more slowly exhibit higher relative retention times than 1.
  • the relative retention times are considered as standard characteristics of the analyzed substance, i.e. they only depend on the chemical structure of the particular constituent.
  • the position of the peak in the chromatogram, or the retention time, is only a quality parameter that does not provide information about the quantity of the analyzed substance.
  • the invention provides especially analytical standards and analytical methods used for the control of the production process and final quality of Fesoterodine Fumarate.
  • One aspect of the present invention is to provide a method of testing the purity of a sample of Fesoterodine or its salt or a pharmaceutical dosage form comprising Fesoterodine, which method comprises assaying the said sample for the presence of compound of formula II or compound of formula III.
  • Another aspect of the present invention is to provide a method of testing the purity of a sample of Fesoterodine or its salt or a pharmaceutical dosage form comprising Fesoterodine, which method further comprises using a sample of compound of formula II or compound of formula III having a purity level of at least 80% as a reference marker.
  • Another aspect of the present invention is to provide compound of formula II or its salt or its enantiomer.
  • Another aspect of the present invention is to provide compound of formula III or its salt or its enantiomer.
  • Another aspect of the present invention is to provide sample of a compound is in substantially pure form.
  • Another aspect of the present invention is to provide method of preparation of the compound of formula II and/or compound of formula III, comprising condensation of Fesoterodine base or its salt with dihydroxy compound of formula VI.
  • Another aspect of the present invention is to provide method of preparation compound of formula II, comprising self condensation of dihydroxy impurity.
  • Another aspect of the present invention is to provide compound of formula V or its salt or its enantiomer.
  • Another aspect of the present invention is to provide method of preparation of the compound of formula V, comprising condensation of dihydroxy compound of formula (VI) with fumaric acid.
  • Another aspect of the present invention is to provide a pharmaceutical composition comprising fesoterodine or a pharmaceutically acceptable salt thereof, and an amount of a compound of formula (II) and/or (III) and/or (V).
  • Another aspect of the present invention is to provide an isolated specific impurity of Fesoterodine Fumarate, selected from the group including formula II, III and formula V and their salts, characterized by chemical purity of more than 50% for use in setting the analytic methods designed for quality control of Fesoterodine Fumarate.
  • Another aspect of the present invention is to provide a vacuum sealed pack comprising Fesoterodine Fumarate wherein the Fesoterodine Fumarate is packaged in oxygen and moisture impermeable package.
  • Another aspect of the present invention is to provide a vacuum sealed pack wherein the pack comprises three layers.
  • Another aspect of the present invention is to provide a vacuum sealed pack wherein the Innermost layer comprises the (LDPE) low density polyethylene bag or (HM, HDPE) high molecular high-density poly ethylene which is vacuum sealed and sealed using heat induction.
  • the Innermost layer comprises the (LDPE) low density polyethylene bag or (HM, HDPE) high molecular high-density poly ethylene which is vacuum sealed and sealed using heat induction.
  • Middle layer is a special plastic bag of (HM, HDPE) high molecular high-density poly ethylene or Triple Laminate Sunlight Barrier (TLSB) bag comprises moisture absorber and nitrogen gas purged and sealed using heat induction.
  • HM, HDPE high molecular high-density poly ethylene
  • TLSB Triple Laminate Sunlight Barrier
  • Another aspect of the present invention is to provide a vacuum sealed pack wherein the Outermost layer is triple laminated aluminum bag inside black coated or quad laminate ultra barrier (QLUB) bag comprises moisture absorber and nitrogen gas purged and sealed using heat induction.
  • QLUB quad laminate ultra barrier
  • Another aspect of the present invention is to provide a vacuum sealed pack wherein the moisture absorber is selected from the group consisting of canister desiccant, desiccant, activated carbon, silicas, zeolites, molecular sieves, hydrogels, calcium oxide and diatomaceous earth.
  • the moisture absorber is selected from the group consisting of canister desiccant, desiccant, activated carbon, silicas, zeolites, molecular sieves, hydrogels, calcium oxide and diatomaceous earth.
  • Another aspect of the present invention is to provide a vacuum sealed pack wherein the bag is put in rigid container.
  • Another aspect of the present invention is to provide a vacuum sealed pack wherein the rigid container is non-airtight/air-tight plastic/metal drums, HDPE (high density polyethylene), PP (polypropylene), LDPE (low density polyethylene), PET, PVC (polyvinyl chloride) drum.
  • HDPE high density polyethylene
  • PP polypropylene
  • LDPE low density polyethylene
  • PET PET
  • PVC polyvinyl chloride
  • Another aspect of the present invention is to provide an improved packing condition for Fesoterodine Fumarate API comprises layers as
  • Middle Special plastic bag of HMHDPE having desiccant, under nitrogen gas purged and heat sealed.
  • Another aspect of the present invention is to provide an improved packing condition for Fesoterodine Fumarate API comprises layers as
  • Middle Triple Laminate Sunlight Barrier (TLSB) bag having canister desiccant, nitrogen gas purged with vacuum and heat sealed.
  • TLSB Triple Laminate Sunlight Barrier
  • QLUB quad laminate ultra barrier
  • Fesoterodine Fumarate must be analyzed for purity, typically by UPLC, HPLC or GC analysis, to determine if it is suitable for continued processing or ultimately for use in a pharmaceutical product.
  • There is eight main known impurities of Fesoterodine Fumarate are available which are characterizes as below.
  • the impurity-A is detected and resolved from fesoterodine fumarate by UPLC with a relative retention time (hereafter referred as RRT) of 0.25.
  • Impurity-B is detected and resolved from fesoterodine fumarate by UPLC with an RRT of 2.28.
  • the impurity-C is detected and resolved from fesoterodine fumarate by UPLC with an RRT of 1.16.
  • the impurity-E is detected and resolved from fesoterodine fumarate by UPLC with an RRT of 0.18.
  • the impurity- F is detected and resolved from fesoterodine fumarate by UPLC with an RRT of 1.46.
  • the impurity-G is detected and resolved from fesoterodine fumarate by UPLC with an RRT of 0.27.
  • Impurity-H is detected and resolved from fesoterodine fumarate by UPLC with an RRT of
  • Impurity-I is detected and resolved from fesoterodine fumarate by UPLC with an RRT of 1.93.
  • the content of the Fesoterodine symmetric dimer impurity (formula II) and asymmetric dimer impurity (formula III), in the target substance must not exceed the limit of 0.15%. Due to the setting of analytic methods for determination of optical purity it is usually necessary to synthesize the standards of both the dimer impurities.
  • the LC system used for method development and forced degradation studies and method validation was Waters-Alliance (manufactured by Waters India Ltd) LC system with a photo diode detector. The out put signal was monitored and processed using Empower software system (designed by Waters India) on IBM computer (Digital Equipment Co).
  • the chromatographic column used was a Waters Aquity BEH CI 8 100mmx2.1 mm column with 1.7 ⁇ particles.
  • the mobile phase consists buffer (1.4 g of Disodium hydrogen phosphate in 1000 mL of water pH-8.0 with ortho phosphoric acid), and solvent is acetonitrile.
  • the flow rate of the mobile phase was kept at 0.3 ml/min. beginning with the gradient ratio of mobile phase buffer and solvent 50:50(v/v), system was continued at the same ratio for 2 minutes. The ratio was changed linearly 30:70(v/v) within 7 minutes and again system was continued at the same ratio for 9 minutes. After 1.5 minutes the initial gradient of 50:50 is for 2.5 minutes to be conditioned for every analysis.
  • the column temperature was maintained at 45 °C and the wavelength was monitored at a wavelength of 220 nm.
  • the injection volume was 3 ⁇ L for related substances determination. Acetonitrile was used as diluent during the standard and test samples preparation.
  • Middle Special plastic bag of HMHDPE having desiccant, under nitrogen gas purged and heat sealed.
  • HMHDPE bag vaccumised and heat sealed.
  • TLSB bag having canister desiccant, nitrogen gas purged with vacuum

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mechanical Engineering (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne de nouvelles impuretés de fésotérodine, une impureté dimère symétrique de fésotérodine et une impureté dimère asymétrique de fésotérodine, et leur procédé de préparation et d'isolement. L'invention concerne également des normes d'analyse et des méthodes d'analyse utilisées pour contrôler le processus de production et la qualité finale de la fésotérodine.
PCT/IB2013/050141 2012-05-18 2013-01-08 Nouveaux marqueurs de référence pour le fumarate de fésotérodine Ceased WO2013046194A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/370,577 US9440910B2 (en) 2012-05-18 2013-01-08 Reference markers for fesoterodine fumarate
EP13704230.5A EP2780317A2 (fr) 2012-05-18 2013-01-08 Nouveaux marqueurs de référence pour le fumarate de fésotérodine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1511/MUM/2012 2012-05-18
IN1511MU2012 2012-05-18

Publications (2)

Publication Number Publication Date
WO2013046194A2 true WO2013046194A2 (fr) 2013-04-04
WO2013046194A3 WO2013046194A3 (fr) 2013-09-19

Family

ID=47714477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/050141 Ceased WO2013046194A2 (fr) 2012-05-18 2013-01-08 Nouveaux marqueurs de référence pour le fumarate de fésotérodine

Country Status (3)

Country Link
US (1) US9440910B2 (fr)
EP (1) EP2780317A2 (fr)
WO (1) WO2013046194A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9751828B2 (en) 2014-07-30 2017-09-05 Dipharma Francis S.R.L. Antimuscarinic compound having a low content of impurities

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
US6713464B1 (en) 1998-05-12 2004-03-30 Schwarz Pharma Ag Derivatives of 3,3-diphenylpropylamines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2416A (en) * 2006-06-09 2012-06-01 Sanol Arznei Schwarz Gmbh Stabilized pharmaceutical compositions comprising fesoterodine.
US20110171274A1 (en) * 2008-07-21 2011-07-14 Actavis Group Ptc Ehf Fesoterodine Substantially Free of Dehydroxy Impurity
KR20120014583A (ko) * 2009-05-11 2012-02-17 라티오팜 게엠베하 타르타르산 염 형태의 데스페소테로딘
IT1394219B1 (it) * 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina fumarato di elevata purezza.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
US6713464B1 (en) 1998-05-12 2004-03-30 Schwarz Pharma Ag Derivatives of 3,3-diphenylpropylamines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9751828B2 (en) 2014-07-30 2017-09-05 Dipharma Francis S.R.L. Antimuscarinic compound having a low content of impurities

Also Published As

Publication number Publication date
WO2013046194A3 (fr) 2013-09-19
EP2780317A2 (fr) 2014-09-24
US20140374284A1 (en) 2014-12-25
US20150175526A2 (en) 2015-06-25
US9440910B2 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
JP6028016B2 (ja) リナグリプチンベンゾエートの多形体
US7294735B2 (en) Purification of cinacalcet
JP2022088624A (ja) 高純度医薬品等級タシメルテオン
US20120258976A1 (en) Crystalline pyrrolo[2,3-d]pyrimidine compounds
US20250282535A1 (en) Pharmaceutical packages and methods of reducing formation of n-nitrosodimethylamine
AU2011274502A1 (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
US20150105422A1 (en) Salts and solvates of a tetrahydroisoquinoline derivative
US11434194B2 (en) Amorphous form of vilanterol trifenatate and processes for the preparation thereof
CN105699524A (zh) 一种替格瑞洛中异构体杂质含量的检测方法
US9440910B2 (en) Reference markers for fesoterodine fumarate
TWI492919B (zh) 實質上不含具有基因毒性作用雜質之羅芬醯胺（ｒａｌｆｉｎａｍｉｄｅ）鹽類的製造方法
KR20230003308A (ko) 듀테트라베나진의 유사체, 이의 제조 및 용도
WO2010136522A2 (fr) Dérivé de pipérazine exempt, ou sensiblement exempt, d'une génotoxicité potentielle, et procédé de préparation associé
TW202434570A (zh) 嘧啶三唑化合物之固體及共晶體形式
CN115381791B (zh) 一种盐酸氟桂利嗪药物组合物
Clarke Crystal Engineering of Multi-Component Crystal Forms: The Opportunities and Challenges in Design
WO2024092614A1 (fr) Produit stable du principe actif pharmaceutique ast-3424, procédé de préparation associé et stockage correspondant
CN112823793A (zh) 一种含有多奈哌齐的透皮贴剂及其制备方法
CN105218383B (zh) 一种盐酸美利曲辛化合物
WO2025232778A1 (fr) Solution concentrée stable pour injection d'ast-3424
EP1715894A2 (fr) Compositions de gabapentine stables
Roy et al. Development and Validation of a Stability Indicating Binary RP-UPLC Method for Determination of Itraconazole in Capsules dosage form
CN120899632A (zh) 稳定的ast-3424原料药乙醇组合物溶液
CN120084894A (zh) 一种绿原酸及其制剂的有关物质的检测方法
US9174944B1 (en) Crystalline lopinavir/surfactant adducts

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2013704230

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14370577

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13704230

Country of ref document: EP

Kind code of ref document: A2